AYA Monograph Colon and Rectal Cancer
Help -
Help for Webmasters
« back to results for ""
Below is a cache of http://seer.cancer.gov/publications/aya/10_colorectal.pdf. It's a snapshot of the page taken as our search engine crawled the Web.
The web site itself may have changed. You can check the current page or check for previous versions at the Internet Archive.
Yahoo! is not affiliated with the authors of this page or responsible for its content.
AYA Monograph Colon and Rectal Cancer
Sheri Spunt, MD
Wayne Furman, MD
Michael La Quaglia, MD
Melissa Bondy, PhD
Richard Goldberg, MD
Chapter 10
Colon and Rectal Cancer
Cancer in 15- to 29-Year-Olds in the United States
CHAPTER 10
COLON & RECTAL CANCER
SEER AYA Monograph
124
National Cancer Institute
HIGHLIGHTS
Incidence
Colorectal carcinoma occcurs in adolescents and young adults at an incidence that increases exponentially between
10 and 35 years of age.
During 1975 to 2000, colorectal cancer accounted for 2.1% of all neoplasms diagnosed in 15- to 29-year-olds.
In the year 2000, an estimated 432 individuals 15 to 29 years of age were diagnosed with cancer of the colon.
The incidence of colorectal carcinoma relative to other cancers rose from 1% in the 15- to 19-year age group, to 1.7%
in the 20- to 24-year age group, to 2.7% in the 25- to 29-year age group.
Males had a higher incidence of colorectal carcinoma than females at all ages, except in individuals 15 to 19 years of age.
Although the incidence of colorectal carcinoma in individuals over 45 years declined during the period 1975 to 2000,
the incidence in 15- to 29-year-olds increased.
The incidence of colorectal carcinoma was approximately equal in white non-Hispanics, Hispanics, African
Americans/blacks, and Asians/Paci c Islanders who were 15 to 29 years of age when diagnosed.
American Indians/Alaska Natives between 20 and 35 years of age tended to have a lower incidence of colorectal
carcinoma than other racial/ethnic groups.
Mortality & Survival
Five-year survival for individuals 15 to 29 years of age was similar to that of older individuals.
Colorectal carcinoma survival improved over time, although it remained relatively stable for individuals in the 15- to
29-year age group.
A 54% 5-year survival rate for colorectal carcinoma for the age group was achieved in the era 1975 to 1980; the
5-year survival rate increased to 58% in the era 1993 to 1999.
Females had higher 5-year survival rates than males at virtually all ages; the disparity was particularly marked in
individuals 15 to 29 years of age.
African Americans/blacks in the 15- to 29-year age group had the worst survival, approximately 20% worse than
whites, non-Hispanics, and Asians/Paci c Islanders.
Whites tended to have the best prognosis.
Risk Factors
Predisposing factors for colorectal carcinoma in children and young adults include hereditary conditions (polyposis
and non-polyposis syndromes), in ammatory bowel disease, and prior radiation exposure.
Hamartomatous polyposis syndromes carry a lower risk of colorectal carcinoma than adenomatous polyposis
syndromes.
INTRODUCTION
Although colorectal carcinoma is among the most
common malignancies of adulthood, the disease is
uncommon in adolescents and young adults. Between
1975 and 2000 in the U.S., colorectal carcinoma
accounted for 2.1% of all neoplasms in adolescents and
young adults 15 to 29 years of age. In the year 2000,
432 individuals in this age group were diagnosed with
colorectal carcinoma in the U.S.
METHODS, CLASSIFICATION SYSTEM, AND
BIOLOGICAL IMPLICATIONS
The International Classi cation of Childhood Cancer
(ICCC) has no speci c category for colorectal cancer.
These cancers are contained with category XI(f), Other
and Unspeci ed Carcinomas, as one of the Carcinomas
and Other Epithelial Neoplasms (category XI). Hence,
the SEER site recode based on the International
Classi cation of Diseases for Oncology (ICD-O) was
used exclusively for this chapter.
National Cancer Institute
125
SEER AYA Monograph
CHAPTER 10
COLON & RECTAL CANCER
For colorectal cancer, the ICD-O Topographical
categories are C18.0-C20.9, C26.0 (colon, rectum, and
intestine NOS) and the ICD-O Morphologic categories
include general carcinomas and adenocarcinomas
(8010-8041, 8140, many others) and speci c cancers of
the colon/rectum. The latter include carcinoid tumors
(8240-8245). No attempt was made to separate cancer of
the colon from rectal cancer. Cancer of the anus is not
included in this chapter.
As explained in the Methods chapter, data are presented for
15- to 29-year-olds with comparisons to the age groups 0 to 15
years and 30 to 44+ years, as appropriate. For some analyses
the entire age range from birth to 85+ years is included. The
absence of data in any gure or table within this chapter
means that too few cases were available for analysis; it does
not mean that the rate or change in rate was zero.
Since the ICCC was set up as a classification for
childhood cancer, it does not have a separate category for
colorectal cancer. Topography and histology from ICD-O
can be used to examine differences among very young
colorectal cancer patients compared to older patients, but
it is clear that this method needs to be complemented
with other biologic determinants such as microsatellite
instability, which is far more common in the colorectal
carcinomas that occur in adolescents and young adults,
as opposed to the sequential gene mutationsincluding
p53 mutationsthat occur in older adults.
INCIDENCE
According to SEER data, colorectal carcinoma accounted
for 2.1% of all malignancies diagnosed in individuals 15
to 29 years of age between 1975 and 2000, and occurred
at a rate of 7.21 per million, age adjusted to the 2000
census and to 5-year age intervals. It was the 11
th
most
common cancer in this age bracket. By using the data in
Trends in Incidence (section below), a total of 432 new
cases of colorectal cancer were estimated to have been
diagnosed in the U.S. in the year 2000 (Table 10.1).
Age-Speci c Incidence
The striking dependence of the incidence of colorectal
carcinoma on age is shown in Figure 10.1. During 1975
to 2000, it increased exponentially between ages 10 and
35, as highlighted by the red line in the semilog plot in
the inset to gure 10.1.
Figure 10.2 shows the incidence of colorectal carcinoma
relative to that of all cancers in 5-year age groups from
0 to 44 years. The incidence of colorectal carcinoma
relative to all cancers increased steadily with advancing
ageagain, even within the 15- to 29-year age group.
Gender-Speci c Incidence
The incidence of colorectal carcinoma in males and
females was similar before age 20, and higher in males
than females older than 20 years. The predilection for male
gender increases with age, such that by 50 years of age,
males had a nearly 50% greater incidence (Figure 10.3).
Racial/Ethnic Differences in Incidence
The incidence of colorectal carcinoma was approximately
equal in white non-Hispanics, Hispanics, African
Americans/blacks, and Asians/Paci c Islanders who were
15 to 29 years of age when diagnosed (Figures 10.4 and
10.5 [the log version of 10.4]). American Indians/Alaska
Natives between 20 and 35 years of age tended to have
a lower incidence of colorectal carcinoma than other
racial/ethnic groups. African Americans/blacks had a
lower incidence from 0 to 20 years of age (Figure 10.5).
Table 10.1: Incidence of Colorectal Carcinoma in Persons Younger Than 30 Years of Age, U.S., 1975-2000
AGE
AT
DIAGNOSIS
(
YEARS
)
<5
5-9
10-14
15-19
20-24
25-29
U.S. population, year 2000 census (in millions)
19.176
20.550
20.528
20.220
18.964
19.381
Average incidence per million, 1975-2000, SEER
^
^
0.6
2.0
5.6
14.6
Average annual % change in incidence, 1975-2000, SEER
^
^
0
0
0
0
Estimated incidence per million, year 2000, U.S.
^
^
0.6
2.0
5.6
14.6
Estimated number of persons diagnosed, year 2000, U.S.
^
^
13
41
107
284
^ Too few for a reliable estimate
CHAPTER 10
COLON & RECTAL CANCER
SEER AYA Monograph
126
National Cancer Institute
Trends in Incidence
Figure 10.6 displays the incidence of colorectal carci-
noma in 5-year age groups over 4 time periods: 1975
to 1980, 1981 to 1986, 1987 to 1992, and 1993 to 2000.
For individuals over 45 years of age, the incidence in
the most recent time period (1993 to 2000) was lower
than during earlier years.
As shown in Figure 10.7, a decline in colorectal carci-
noma incidence in younger individuals was not readily
apparent. The rarity of colorectal carcinoma in patients
under 45 years of age may explain the dif culty in iden-
tifying a trend in incidence in this age group.
Figure 10.8 displays the average annual percent change
in incidence of colorectal carcinoma by age group dur-
ing the years 1975 to 2000. The incidence of colorectal
carcinoma in patients in the 15- to 29-year age group
increased during this period, whereas the incidence in
patients over 30 years of age declined.
OUTCOME
Mortality
As with incidence (Figure 10.7), mortality of colorectal
cancer was directly proportional to age and was higher
in males than females (Figure 10.9). In the U.S., African
Americans/blacks had higher mortality from colorectal
carcinoma than any other racial/ethnic group. This was
true not only for older adults but also for young adults
25 years of age and older (Figure 10.10).
Figure 10.1: Incidence of Colorectal Carcinoma, SEER 1975-2000
Figure 10.2: Incidence of Colorectal Cancer Relative to All
Cancer, SEER, 1975-2000
Figure 10.3: Incidence of Colorectal Carcinoma by Gender,
SEER 1975-2000
Figure 10.4: Incidence of Colorectal Carcinoma by Race/
Ethnicity, SEER 1992-2000
National Cancer Institute
127
SEER AYA Monograph
CHAPTER 10
COLON & RECTAL CANCER
Since 1975, colorectal carcinoma mortality has declined
among 15- to 29-year-olds (Figure 10.11), despite the in-
creased incidence in this age group (Figure 10.8). The re-
duction in national colorectal cancer mortality during the
past quarter century averaged 1.4% per year in patients
younger than age 45 (p < 0.05), and the decline was also
statistically signi cant in each 5-year age group under
age 45 (Figure 10.12). There is a suggestion that the trend
in national colorectal cancer mortality reduction is di-
rectly proportional to age, with patients younger than 35
years of age experiencing less of a reduction in mortality
than those 35 to 44 years of age (Figure 10.12).
Survival
Five-year survival of individuals with colorectal carci-
noma 15 years of age and older was between 50% and
61% for all ve-year age groups (Figure 10.13). Five-year
survival rates improved in successive eras, though rates
for individuals 15 to 29 years of age remain ed relatively
stable (Figure 10.14).
Gender-Speci c Survival
Females had a consistently higher 5-year survival rate
compared to males; this was most apparent in patients
younger than 40 years of age (Figures 10.15 and 10.16)
Racial/Ethnic Differences in Survival
Survivalas a function of race/ethnicityfor 15- to
29-year-olds diagnosed with colorectal cancer dur-
ing the period 1992 to 1999 is shown in Figure 10.17.
African Americans/blacks had the worst survival in
this age group. White non-Hispanics, Hispanics, and
Figure 10.7: Change in Incidence of Colorectal Carcinoma by
Era, SEER 1975-2000
Figure 10.8: Average Annual Percent Change (A APC) in
Incidence of Colorectal Carcinoma, SEER 1975-2000
Figure 10.5: Incidence of Colorectal Carcinoma by Race/
Ethnicity, SEER 1992-2000
Figure 10.6: Change in Incidence of Colorectal Carcinoma by
Era, SEER 1975-2000
CHAPTER 10
COLON & RECTAL CANCER
SEER AYA Monograph
128
National Cancer Institute
Asians/Pac i c Islanders had comparable survival, which
was from 15% to 20% better than for African Americans/
blacks as early as 1 year after diagnosis and persisting
for at least ve years. Whites (including Hispanic whites)
tended to have the best prognosis.
Survival According Extent of Disease
Figure 10.18 displays 5-year survival rates for individuals
with colorectal carcinoma according to disease extent.
There were no apparent differences in survival in indivi-
duals 15 to 29 years of age compared to older individuals.
RISK FACTORS
Predisposing factors for colorectal carcinoma in children
and young adults include hereditary conditions affecting
the bowel (polyposis and nonpolyposis syndromes), in-
ammatory bowel disease, and radiation exposure. Ap-
proximately 15 to 20% of colorectal cancer patients have
familial colon cancer without a de ned genetic pattern,
1
about 5% have hereditary nonpolyposis colon cancer,
2
and 1% have hereditary polyposis syndromes.
3
Hereditary Nonpolyposis Colon Cancer (HNPCC)
HNPCC was de ned by Lynch,
4
who observed a number
of families with an increased risk of colon cancer in the
absence of polyposis. HNPCC accounts for approximate -
ly 5% of all colorectal cancer cases and is associated with
an early age at diagnosis, proximal colonic site predomi-
nance, mucinous phenotype and multiple synchronous
and metachronous tumors.
5,6
Families with HNPCC
also have a higher incidence of other tumors, including
stomach, small intestine, hepatobiliary system, ovary,
Figure 10.9: National Mortality of Colorectal Carcinoma by
Gender, U.S., 1975-2000
Figure 10.10: National Mortality of Colorectal Carcinoma by
Race/Ethnicity, U.S., 1975-2000
Figure 10.11: National Mortality of Colorectal Carcinoma by Era,
U.S
Figure 10.12: Average Annual Percent Change (AAPC) in
National Mortality, Colorectal Carcinoma, 1975-2000
National Cancer Institute
129
SEER AYA Monograph
CHAPTER 10
COLON & RECTAL CANCER
endometrium, and upper urinary tract cancers.
7
HNPCC
is associated with a lower stage at diagnosis, a lower
incidence of metastases, and a better prognosis than spor-
adic colorectal carcinoma.
8
Germline mutations of DNA mismatch repair genes are
responsible for the predisposition to colorectal carcinoma
among patients with HNPCC. Absence of normal mis-
match repair function in colonic epithelial cells leads to
microsatellite instability and malignant transformation.
9
The Amsterdam criteria for de ning HNPCC
10
include
colorectal cancer in at least three individuals spanning
two generations, at least one of whom is a rst-degree rela-
tive of the other two. In a small series of colorectal cancer
patients who were 21 years of age or less at diagnosis,
microsatellite instability was observed in about half,
though few ful lled the diagnostic criteria for HNPCC.
11
Polypoid Disease of the Gastrointestinal Tract
Colonic polyps can be divided by histology into adenoma-
tous and hamartomatous categories. Adenomatous polyps
represent a growth alteration in the colonic mucosa result-
ing in neoplastic proliferation and substantial malignant
potential. Hamartomatous polyps, though less proliferative
in nature, are also associated with a signi cant cancer risk.
Hamartomatous Polyposis Syndromes
Only two hamartomatous polyposis syndromes have been
clearly associated with an increased risk of colorectal
carcino ma. Juvenile polyposis, which encompasses
juven ile polyposis coli and diffuse juvenile polyposis,
Figure 10.15: 5-Year Survival Rate for Colorectal
Carcinoma by Gender, SEER 1975-1999
20
40
60
0
Age at Diagnosis (Years)
15-
19
20-
24
25-
29
30-
34
35-
39
40-
44
45-
49
50-
54
55-
59
60-
64
65-
69
70-
74
75-
79
5-Year
Survival
(%)
80-
84
Female
Male
Figure 10.13: 5-Year Survival Rate for Colorectal Carcinoma,
SEER 1975-1999
Figure 10.14: 5-Year Survival Rate for Colorectal Carcinoma
by Era, SEER
Figure 10.15: 5-Year Survival Rate for Colorectal Carcinoma by
Gender, SEER 1975-1999
Figure 10.16: 5-Year Survival Rate for Colorectal Carcinoma by
Gender, SEER 1975-1999
CHAPTER 10
COLON & RECTAL CANCER
SEER AYA Monograph
130
National Cancer Institute
Peutz-Jeghers syndrome,
17
characterized by variable
mucocutaneous pigmentation abnormalities and gastro-
intestinal hamartomas, is also associated with an
increased risk of colorectal malignancy. These patients
typ ically present during childhood with recurrent intussus-
ception/bowel obstruction, rectal bleeding, anemia, and
rectal prolapse, in some cases before the pigmentary
changes classically associated with the disorder are pre-
sent.
18
Males become symptomatic at an earlier age (peak
5-10 years) than females (peak 10-15 years). Hamartoma-
t ous polyps of the small intestine are most common;
however, about one-third of patients also have colorectal
involvement. Most cases of Peutz-Jeghers syndrome are
due to germline mutation of the STK11 gene, which
encodes a serine threonine kinase.
19
The transformation
from hamartoma to adenocarcinoma in patients with
germ line STK11 mutations depends on additional somatic
mutations.
20
In an analysis of 33 patients with Peutz-
Jeghers syndrome, the standardized mortality ratio for
gastrointestinal cancer was 24.8.
21
Adenomatous Polyposis Syndromes
The familial adenomatous polyposis (FAP) syndromes
are characterized by the early development of multiple
adenomatous colonic polyps. FAP affects about 1 in
7,000 individuals.
9
Virtually all patients with FAP will
develop colorectal carcinoma unless a total colectomy
is performed prior to the onset of malignancy. FAP is
an autosomal dominant trait with high but variable
penetrance; 10 to 20% of cases are de novo muta-
tions without any apparent family history. Mutations
in the APC gene at 5q21 are responsible for the FAP
syndrome.
22
The clinical phenotype, including the pres-
ence or absence of extracolonic abnormalities, appears to
vary according to the exact site of APC gene mutation and
the presence of modifying genes.
23,24
Two types of FAP
seem to exist, and a relationship between the location
of mutations in the gene and the phenotypic expression
of FAP has been established:
25
the sparse type, which
is characterized by hundreds of polyps, and the profuse
type, which presents with thousands of polyps. Patients
with the profuse type tend to develop adenocarcinoma at
an earlier age. FAP is associated with the development of
extracolonic malignancies, including periampullary and
thyroid carcinomas and hepatoblastoma.
26,27
typically presents with rectal bleeding and anemia in
patients between 4 and 30 years of age.
12,13
Other symptoms
include intussusception or bowel obstruction, rectal or polyp
prolapse, abdominal pain, and protein-losing enteropathy.
The polyps may occur throughout the gastrointestinal
tract, but most often affect the stomach, distal colon, and
rectum. Juvenile polyposis is transmitted as an autosomal
dominant trait; SMAD4 and BMPR1A gene mutations
have been implicated in the etiology of this syndrome.
14
In
a review of cases reported in the English literature, Coburn
et al. found that 17% of patients developed gastrointestinal
malignancies, at a mean age of 35.5 years (range, 4-60
years).
15
The cumulative risk of colorectal malignancy has
been reported to be 68% by 60 years of age.
16
Figure 10.17: Relative Survival for Colorectal Carcinoma by
Race/Ethnicity, SEER 1992-1999
Figure 10.18: 5-Year Survival Rate for Colorectal Cancer by
Extent of Disease, SEER 1975-2000
National Cancer Institute
131
SEER AYA Monograph
CHAPTER 10
COLON & RECTAL CANCER
A proportion of FAP patients have Gardners syndrome,
28
which includes desmoid tumors, cysts of the mandible,
bromas, osteomas, and congenital hypertrophy of the
retinal pigment epithelium. Desmoid tumors of the
abdominal wall and mesentery occur in a signi cant
proportion of these patients, and are a leading cause of
death in post-colectomy patients.
Other syndromes associated with FAP include Turcots
syndrome
29
and Old elds syndrome.
30
Patients with
Turcots syndrome manifest multiple pediatric brain tumors
(medulloblastoma, gliomas, and others) in conjunction
with FAP. Hamilton et al. found that two distinct germ-
line defects, mutation of the APC gene and mutation of a
mismatch-repair gene may each give rise to Turcots syn-
drome.
31
The type of brain tumor correlates with the muta-
tion, with medulloblastomas characteristic of APC-related
mutations and glioblastoma multiforme seen in patients
with mismatch-repair gene mutations. Old elds syndrome
includes FAP in association with multiple sebaceous cysts.
In ammatory Bowel Disease
Ulcerative colitis is clearly associated with the devel-
opment of colorectal carcinoma.
32
The age at initial
presen tation and extent of colonic involvement are strong
independent risk factors for subsequent development of
colorectal cancer.
33
Patients less than 15 years of age
at diagnosis and those with involvement of the entire
colon are at the highest risk. The cumulative risk of colo-
rectal carcinoma in individ uals less than 40 years of
age with pancolitis was 13% at 25 years from diagno-
sis. Synchronous colorectal tumors are more common in
patients with ulcerative colitis than in the remainder of
the population with colorectal carcinoma.
34
In a report
by Lashner et al.,
35
11 of 15 ulcerative colitis patients
with strictures were found to have carcinomas on biop-
sy. Thus, patients who develop colonic strictures should
be considered to have carcinomas until proven other-
wise, and stricture formation is an indication for surgery.
Crohns disease, when it involves the colon or rectum, is
associated with an increased risk of colorectal carcinoma.
The relative risk is quite high (20.9 odds ratio) in those in
whom the diagnosis is made before the age of 30 years.
36
About one-third of the colorectal carcinomas in patients
with Crohns disease are mucinous adenocarcinoma.
37
Other Factors Predisposing to Colorectal Carcinoma
Colorectal carcinoma has been reported in patients with
Bloom syndrome, a rare autosomal recessive disorder
caused by germline mutations of the BLM gene.
38
Gruber
et al. showed recently that carriers of BLM mutations are
also at increased risk of colorectal carcinoma.
39
About
5% of patients undergoing urinary diversion with ureter-
osigmoidostomy develop colon cancer, probably due to
chronic in ammation caused by the mixture of feces and
urine at the implant site.
40
Colorectal Carcinoma in Childhood Cancer Survivors
Children who receive abdominal or pelvic radiation
therapy for the treatment of a malignancy are at increased
risk for early development of colorectal cancer in the ra-
diation eld.
41,42
This may be particularly problematic in
any child who has one of the above genetic predisposi-
tions. Overall, however, colorectal cancer is one of the
least common second cancers in long-term survivors of
childhood cancer.
43-46
SUMMARY
Colorectal carcinoma accounted for 2.1% of all malig-
nancies in individuals between 15 and 29 years of age,
and was the 11
th
leading cause of cancer in this age group.
The average annual incidence of colorectal carcinoma
was 7.2 per million in 15- to 29-year-old individuals. The
incidence of colorectal carcinoma rose with advancing
age, even within the 15- to 29-year age group. Colo rectal
carcinoma accounted for an increasing proportion of all
malignancies with advancing age. While it accounted for
only 1% of malignancies in the 15- to 19-year age group,
it was responsible for 2.7% of cancers in the 25- to 29-
year age group. Colorectal carcinoma was more common
in males at all ages over 20 years of age. Although the
incidence of colorectal carcinoma has declined over time
in individuals over 45 years of age, a similar decline has
not been observed in individuals in the 15- to 29-year
age group. The small number of patients diagnosed with
colorectal carcinoma in this age group makes it dif cult
to draw conclusions about incidence and outcome data.
The average percent annual change in the incidence of
colorectal carcinoma increased between 1975 and 2000
among individuals 15 to 29 years of age, and declined in
individuals over 30 years of age.
CHAPTER 10
COLON & RECTAL CANCER
SEER AYA Monograph
132
National Cancer Institute
Five-year survival rates for individuals with colorectal
carcinoma in the 15- to 29-year age group were similar to
those for older individuals. The survival improvements
over time observed in individuals over 45 years of age
have also been noted in individuals 15 to 29 years of
age. Females with colorectal carcinoma had a superior 5-
year survival compared to males at virtually all ages; the
dispar ity was particularly marked in individuals younger
than 40 years of age.
Risk factors for the development of colorectal carcinoma
in childhood and young adulthood include hereditary
conditions (polyposis and non-polyposis syndromes), in-
ammatory bowel disease, and radiation exposure. Hamar-
tomatous polyposis syndromes carry a lower risk of colo-
rectal carcinoma than adenomatous polyposis syndromes.
Colorectal carcinoma has also been reported in individuals
with Bloom syndrome and in those who have undergone
urinary diversion via ureterosigmoidostomy.
REFERENCES
1. Boutron M-C, Faivre J, Quipourt V, et al.: Family history of colorectal tumours and implications for the adenoma-
carcinoma sequence: a case control study. Gut 1995;37:830-4.
2. Marra G, Boland CR: Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives.
J Natl Cancer Inst 1995;87:1114-25.
3. Vogelstein B: Genetic testings for cancer: the surgeons critical role. Familial colon cancer. J Am Coll Surg 1999;188:74-9.
4. Lynch HT, de la Chapelle A: Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999;36:801-18.
5. Lynch HT, Smyrk T, Lynch J: An update of HNPCC (Lynch syndrome). Cancer Genet Cytogenet 1997;93:84-99.
6. Mecklin JP, Sipponen P, Jarvinen H: Histopathology of colorectal carcinomas and adenomas in cancer family
syndrome. Dis Colon Rectum 1986;29:849-53.
7. Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71:677-85.
8. Watson P, Lin KM, Rodriguez-Bigas MA et al.: Colorectal carcinoma survival among hereditary nonpolyposis
colorectal carcinoma family members. Cancer 1998;83:259-66.
9. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
10. Vasen HF, Mecklin JP, Meera Khan P, et al.: The International Collaborative Group on Herediatry Non-Polyposis
Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5.
11. Datta RV, LaQuaglia MP, Paty PB: Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl
J Med 2000;342:137-8.
12. Luk GD: Diagnosis and therapy of hereditary polyposis syndromes. Gastroenterologist 1995;3:153-67.
13. Desai DC, Neale KF, Talbot IC, et al.: Juvenile polyposis. Br J Surg 1995;82:14-7.
14. Sayed MG, Ahmed AF, Ringold JR, et al.: Germline SMAD4 or BMPR1A mutations and phenotype of juvenile
polyposis. Ann Surg Oncol 2002;9:901-6.
15. Coburn MC, Pricolo VE, DeLuca FG, et al.: Malignant potential in intestinal juvenile polyposis syndromes. Ann
Surg Oncol 1995;2:386-91.
16. Murday V, Slack J: Inherited disorders associated with colorectal cancer. Cancer Surv 1989;8:139-57.
17. Jeghers H, McKusick VA, Katz KH: Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and
digits; a syndrome of diagnostic signi cance. N Engl J Med 1949;241:1031-6.
18. Tovar JA, Eizaguirre I, Albert A, et al.: Peutz-Jeghers syndrome in children: report of two cases and review of the
literature. J Pediatr Surg 1983;18:1-6.
19. Jenne DE, Reimann H, Nezu J, et al.: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine
kinase. Nat Genet 1998;18:38-43.
20. Gruber SB, Entius MM, Petersen GM, et al.: Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer
Res 1998;58:5267-70.
National Cancer Institute
133
SEER AYA Monograph
CHAPTER 10
COLON & RECTAL CANCER
21. Lim W, Hearle N, Shah B, et al.: Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers
syndrome. Br J Cancer 2003;89:308-13.
22. Kinzler KW, Nilbert MC, Su LK, et al.: Identi cation of FAP locus genes from chromosome 5q21. Science 1991;253:661-5.
23. Caspari R, Olschwang S, Friedl W, et al.: Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic
lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995;4:337-40.
24. Scott RJ, Taeschner W, Heinimann K, et al.: Association of extracolonic manifestations of familial adenomatous
polyposis with acetylation phenotype in a large FAP kindred. Eur J Hum Genet 1997;5:43-9.
25. Spirio L, Otterud B, Stauffer D, et al.: Linkage of a variant or attenuated form of adenomatous polyposis coli to the
adenomatous polyposis coli (APC) locus. Am J Hum Genet 1992;51:92-100.
26. Cetta F, Montalto G, Gori M, et al.: Germline mutations of the APC gene in patients with familial adenomatous polyposis-
associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab 2000;85:286-92.
27. Giardiello FM, Petersen GM, Brensinger JD, et al.: Hepatoblastoma and APC gene mutation in familial adenomatous
polyposis. Gut 1996;39:867-9.
28. Gardner EJ: Follow-up study of a family group exhibiting dominant inheritance for a syndrome including intestinal
polyps, osteomas, bromas and epidermal cysts. Am J Hum Genet 1962;14:376-90.
29. Turcot J, Despres JP, St Pierre F: Malignant tumors of the central nervous system associated with familial polyposis
of the colon: report of two cases. Dis Colon Rectum 1959;2:465-8.
30. Old eld MC: The association of familial polyposis of the colon with multiple sebaceous cysts. Br J Surg 1954;41:534-41.
31. Hamilton SR, Liu B, Parsons RE, et al.: The molecular basis of Turcots syndrome. N Engl J Med 1995;332:839-47.
32. Mir-Madjlessi SH, Farmer RG, Easley KA, et al.: Colorectal and extracolonic malignancy in ulcerative colitis. Cancer
1986;58:1569-74.
33. Ekbom A, Helmick C, Zack M, et al.: Ulcerative colitis and colorectal cancer. A population-based study. N Engl J
Med 1990;323:1228-33.
34. Greenstein AJ, Slater G, Heimann TM, et al.: A comparison of multiple synchronous colorectal cancer in ulcerative
colitis, familial polyposis coli, and de novo cancer. Ann Surg 1986;203:123-8.
35. Lashner BA, Turner BC, Bostwick DG, et al.: Dysplasia and cancer complicating strictures in ulcerative colitis. Dig
Dis Sci 1990;35:349-52.
36. Ekbom A, Helmick C, Zack M, et al.: Increased risk of large-bowel cancer in Crohns disease with colonic involvement.
Lancet 1990;336:357-9.
37. Rubio CA, Befrits R: Colorectal adenocarcinoma in Crohns disease: a retrospective histologic study. Dis Colon
Rectum 1997;40:1072-8.
38. Karnak I, Ciftci AO, Senocak ME, et al.: Colorectal carcinoma in children. J Pediatr Surg 1999;34:1499-504.
39. Gruber SB, Ellis NA, Scott KK, et al.: BLM heterozygosity and the risk of colorectal cancer. Science 2002;297:2013.
40. Eraklis AJ, Folkman MJ: Adenocarcinoma at the site of ureterosigmoidostomies for exstrophy of the bladder. J Pediatr
Surg 1978;13:730-4.
41. Densmore TL, Langer JC, Molleston JP, et al.: Colorectal adenocarcinoma as a second malignant neoplasm following
Wilms tumor and rhabdomyosarcoma. Med Pediatr Oncol 1996;27:556-60.
42. LaQuaglia MP, Heller G, Filippa DA, et al.: Prognostic factors and outcome in patients 21 years and under with
colorectal carcinoma. J Pediatr Surg 1992;27:1085-90.
43. Jenkinson HC, Hawkins MM, Stiller CA, et al.: Long-term population-based risks of second malignant neoplasms
after childhood cancer in Britain. Brit J Cancer 2004;91:1905-10.
44. Haddy TB, Mosher RB, Dinndorf PA, Reaman GH: Second neoplasms in survivors of childhood and adolescent
cancer are often treatable. J Adolesc Health 2004;4:324-9.
45. Klein G, Michaelis J, Spix C, et al.: Second malignant neoplasms after treatment of childhood cancer. Eur J Cancer
2003;39:808-17.
46. Bhatia S, Sklar C: Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002;2:124-32.
498 comments
tag: Training
filetype:pdf
file time: 2008-08-04
file size:691267
Click Here To Download...